Timothy Cannon, MD
Medical Oncology · Fairfax, VANPI 1376719906
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $10,178 of the $10,716 with a category attached, or 95.0%. 10 manufacturers reported payments, led by AstraZeneca at 44.7% of the total.
Across 13 payments — averaging $824.31 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$5K
- Sirtex Medical Inc$3K
- Mirati Therapeutics, Inc.$1K
- Bayer$900
- Deciphera Pharmaceuticals Inc.$400
- Astellas Pharma US Inc$153
- plus $276 from 4 others
Across 148 payments — averaging $12,903 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Merck$948K
- G1 Therapeutics, Inc.$804K
- Janssen Research & Development, LLC$78K
- Halozyme Inc$59K
- Organon$16K
- AstraZeneca$5K
What the payments were for
- Consulting fees$10,17895%
- Food & beverage$4124%
- Education$1271%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 2 | $4,790 |
| Sirtex Medical Inc | 2 | $2,710 |
| Mirati Therapeutics, Inc. | 1 | $1,488 |
| Bayer | 1 | $900 |
| Deciphera Pharmaceuticals Inc. | 1 | $400 |
| Astellas Pharma US Inc | 2 | $153 |
| Abbott | 1 | $118 |
| Angiodynamics, Inc. | 1 | $72 |
| GSK | 1 | $67 |
| Jazz Pharmaceuticals Inc. | 1 | $19 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- IMFINZI$2,740
- SIR-Spheres Microspheres$2,710
- KRAZATI$1,488
- Stivarga$900
- QINLOCK$400
- Optis Coronary Imaging System$118
How this compares
$10,716 in reported general payments places this provider in the 75th percentile of 95 medical oncology providers in Virginia.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| QinlockRipretinib | 15 | $624,868 |
| LenvimaLenvatinib Mesylate | 11 | $268,872 |
| CreonLipase/Protease/Amylase | 54 | $187,467 |
| RubracaRucaparib Camsylate | 13 | $186,345 |
| LonsurfTrifluridine/Tipiracil Hcl | 26 | $150,443 |
| Sandostatin Lar DepotOctreotide Acetate,mi-Spheres | 11 | $50,496 |
| EliquisApixaban | 84 | $44,564 |
| VemlidyTenofovir Alafenamide | 11 | $16,552 |
| XareltoRivaroxaban | 13 | $14,038 |
| Ondansetron Hcl | 73 | $3,251 |
| Olanzapine | 55 | $736 |
| Dexamethasone | 48 | $675 |
| Sucralfate | 16 | $660 |
| Ondansetron OdtOndansetron | 21 | $586 |
| Famotidine | 21 | $581 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Deciphera Pharmaceuticals Inc.Qinlock | $400 | $624,86815 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 95 medical oncology providers in Virginia.
Other medical oncology in Fairfax
- Janakiraman SubramanianFairfax$562K
- Alexander SpiraFairfax$533K
- Roy BeveridgeFairfax$216K
- Kathleen HarndenFairfax$195K
- Nagla Abdel KarimFairfax$131K
- Lauren MauroFairfax$53K
- Donald TrumpFairfax$20K
- Arthur WinerFairfax$10K
- Danijela JelovacFairfax$7K
- Eun-Mi YuFairfax$7K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.